La semaglutida es un agonista del receptor de GLP-1 aprobado para la diabetes tipo 2 (Ozempic) y la obesidad (Wegovy); reduce el apetito y el peso corporal y mostró beneficio cardiovascular en el ensayo SELECT.
Long-acting agonist at the GLP-1 receptor. Structurally a modified glucagon-like peptide 1 whose long half-life is achieved via a fatty-acid side chain and reversible albumin binding. Acts centrally on satiety and peripherally on glucose-dependent insulin secretion and delayed gastric emptying.
Curva teórica de concentración con una semivida de 165 h. Modelo farmacocinético puro — no es una recomendación de dosis.
Open in PK tool →The FDA prescribing information carries a boxed warning on thyroid C-cell tumours based on rodent-model findings. Human relevance of these findings is not established. Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 is a contraindication.
The EMA authorised Ozempic for the treatment of adults with insufficiently controlled type-2 diabetes as an adjunct to diet and exercise — as monotherapy or in combination with other antidiabetic medicinal products.
Los péptidos vienen como polvo seco. Una vez disuelto en un líquido (reconstitución), esta calculadora responde a una única pregunta: ¿cuánta sustancia hay en un mililitro de solución después?
Solo ciencia, sin ventas. Cancela cuando quieras.
We store your email only for the newsletter. Unsubscribe anytime. Privacy